Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship

Company: bioMérieux Date: 2025-04-07 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

# **bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship**

**Marcy l'Étoile, France, April 7 th , 2025 – bioMérieux, a world leader in the field of** *in vitro* **diagnostics, announces the CE marking of LUMED™ APSS™, an advanced clinical decision support system (CDSS) designed to enhance antimicrobial stewardship programs (ASP) and improve patient outcomes.**

Antimicrobial resistance (AMR) poses a significant global health threat, with the World Health Organization ranking it among the top public health threats worldwide<sup>1</sup> . Each year, AMR is responsible for approximately 1.27 million deaths<sup>2</sup> . Health information technologies – including clinical decision support systems – are crucial in combating this issue. They enable faster and more accurate identification of pathogens and resistance mechanisms, allowing healthcare providers to make data-driven decisions and select the most effective treatments promptly.

LUMED™ APSS™ is a software solution designed for infectious disease (ID) pharmacists and physicians as an aid to address the challenges of antimicrobial overuse and misuse, which contribute to the rise of drug-resistant organisms. The system's multistep process helps ensure antimicrobial treatments are continuously evaluated and adjusted based on the latest clinical data, promoting the de-escalation of unnecessary treatments and the use of oral alternatives when appropriate.

The solution also includes support and training for medical teams to ensure a seamless implementation of LUMED™ APSS™ and help them adopt best practices in antibiotic therapy. It is tailored to meet the unique needs of Antimicrobial Stewardship (AMS) committees in hospitals.

*"bioMérieux is committed to advancing healthcare through innovative diagnostic solutions. The introduction of LUMED™ APSS™ is a game-changer for antimicrobial stewardship. Its ability to provide real-time alerts and prioritize patient reviews based on local practice contexts is invaluable. This system not only supports optimal antimicrobial prescribing but also helps improve patient safety and reduce healthcare costs<sup>3</sup> ,"* stated Dr Charles K. Cooper, Executive Vice President, Chief Medical Officer, bioMérieux.

The LUMED™ APSS™ clinical decision support system was developed by Lumed, a Canada-based company [acquired by bioMérieux in 2024.](https://www.biomerieux.com/corp/en/journalists/press-releases/acquisition-lumed-software-fight-against-antimicrobial-resistance.html) Additionally, an advanced surveillance module, LUMED™ ZINC™ is available to help prevent infections in hospitals. LUMED™ solutions complete bioMérieux's portfolio dedicated to Antimicrobial Stewardship (AMS – see below) and also strengthen its suite of digital solutions called BIOMÉRIEUX VISION SUITE.

*"Data-driven diagnostic support tools, such as LUMED™, go beyond the lab, empowering healthcare professionals with real-time antimicrobial assessment for informed therapy decisions, while helping hospitals optimize Antimicrobial Stewardship programs ― driving improved patient, healthcare, and economic outcomes. LUMED™ APSS™ strengthens bioMérieux's comprehensive portfolio of solutions to advance Antimicrobial Stewardship and combat Antimicrobial Resistance, reinforcing our commitment to preserve antibiotic efficacy both now and for future generations,"* added Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux.

![](_page_1_Picture_0.jpeg)

Already available in several countries, LUMED™ APSS™ will now be deployed throughout Europe thanks to the CE-marking. An extended roll out worldwide is planned in the coming years.

*<sup>1</sup> <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>*

*<sup>2</sup> Murray CJ. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet. 2022;399(10325):629-655. doi:https://doi.org/10.1016/S0140-6736(21)02724-0.*

*<sup>3</sup> Nault V, Pepin J, Beaudoin M, Perron J, Moutquin JM, Valiquette L. Sustained impact of a computer-assisted antimicrobial stewardship intervention on antimicrobial use and length of stay. J Antimicrob Chemother. 2017 Mar 1;72(3):933-940. doi: 10.1093/jac/dkw468. PMID: 27999034.*

### **ABOUT BIOMÉRIEUX'S COMPLETE ANTIMICROBIAL STEWARDSHIP (AMS) SOLUTION**

bioMérieux's healthcare mission is to help sustain the use of antibiotic efficacy for generations to come. To support hospitals, institutions, and laboratories with their AMS programs, bioMérieux has a complete solution covering antibiotic therapy initiation, optimization, and discontinuation. This constantly evolving offer provides timely, accurate results to adjust therapy, transforms data into actionable insights, and integrates smoothly into any hospital with its flexible partnership approach. bioMérieux has more than 60 years of microbiology expertise with 75% of its R&D directed to research on antimicrobial resistance to ensure the current offer evolves to meet customers' AMS needs.

### **ABOUT BIOMÉRIEUX**

#### *Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4 billion, with over 93% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products.

[www.biomerieux.com.](http://www.biomerieux.com/)

bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg: BIM.FP

## **CONTACTS**

### *Investor Relations*

Aymeric Fichet Tel.: +33 (0)4 78 87 20 00 [investor.relations@biomerieux.com](mailto:investor.relations@biomerieux.com)

*Media Relations*

**bioMérieux United States France** [media@biomerieux.com](mailto:media@biomerieux.com) [lizad@seeztoday.com](mailto:lizad@seeztoday.com) [lheilbronn@image7.fr](mailto:lheilbronn@image7.fr)

Romain Duchez Liza Deckelbaum (Seez) Laurence Heilbronn (Image 7) Tel.: +33 (0)4 78 87 21 99 Tel.: 919.645.0782 Tel.: +33 (0)1 53 70 74 64